IRIDEX (NASDAQ:IRIX) Stock Price Crosses Below Two Hundred Day Moving Average – What’s Next?

Posted by Geri Gentry on Jul 12th, 2026

IRIDEX Corporation (NASDAQ:IRIX – Get Free Report) passed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $1.21 and traded as low as $1.10. IRIDEX shares last traded at $1.10, with a volume of 75,644 shares changing hands.

Analysts Set New Price Targets

Separately, Weiss Ratings upgraded shares of IRIDEX from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, July 1st. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, IRIDEX has an average rating of “Hold” and an average price target of $3.00.

View Our Latest Stock Report on IRIX

IRIDEX Price Performance

The firm has a market capitalization of $19.15 million, a price-to-earnings ratio of -5.79 and a beta of 0.63. The stock has a 50 day moving average price of $1.10 and a two-hundred day moving average price of $1.21.

IRIDEX (NASDAQ:IRIX – Get Free Report) last announced its earnings results on Tuesday, May 19th. The medical equipment provider reported ($0.03) EPS for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.04. The firm had revenue of $11.80 million for the quarter, compared to analysts’ expectations of $11.91 million.

Hedge Funds Weigh In On IRIDEX

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Thompson Davis & CO. Inc. purchased a new stake in shares of IRIDEX during the fourth quarter worth $32,000. Jane Street Group LLC grew its stake in IRIDEX by 93.9% during the 4th quarter. Jane Street Group LLC now owns 31,758 shares of the medical equipment provider’s stock worth $36,000 after purchasing an additional 15,377 shares in the last quarter. Diversify Wealth Management LLC acquired a new position in IRIDEX during the 1st quarter worth $35,000. Perkins Capital Management Inc. increased its holdings in IRIDEX by 33.9% during the 1st quarter. Perkins Capital Management Inc. now owns 55,300 shares of the medical equipment provider’s stock worth $56,000 after purchasing an additional 14,000 shares during the period. Finally, Susquehanna International Group LLP increased its holdings in IRIDEX by 46.2% during the 3rd quarter. Susquehanna International Group LLP now owns 56,470 shares of the medical equipment provider’s stock worth $65,000 after purchasing an additional 17,834 shares during the period. Hedge funds and other institutional investors own 20.10% of the company’s stock.

IRIDEX Company Profile

(Get Free Report)

IRIDEX Corporation (NASDAQ: IRIX) is a medical technology company specializing in the development, manufacturing and commercialization of innovative ophthalmic laser and imaging systems. The company’s offerings focus on energy-based therapies designed to treat retinal vascular disorders, glaucoma and other ocular conditions. IRIDEX’s portfolio includes laser photocoagulation platforms, micro-pulse laser technology, and related consumable devices for use by ophthalmologists and retina specialists.

The company’s flagship products include the Cyclo G6 Glaucoma Laser System, which delivers precise, controlled micro-pulse laser therapy for patients with refractory glaucoma, and the IQ 532 Retina Laser System, designed to support minimally invasive laser treatments for diabetic retinopathy and age-related macular degeneration.